Kilitch Drugs profit falls 82% as quarterly revenue rises 14%

Kilitch Drugs reported consolidated profit after tax of Rs 141.24 lakh for the quarter ended September 30, 2026, down 82% from Rs 8.04 crore a year earlier, although revenue from operations rose 14% to Rs 50.215 crore. Total income declined because other income was lower, while several expense lines increased and the foreign subsidiary reported a loss.

Why did Kilitch Drugs' profit fall despite higher quarterly revenue?

Kilitch Drugs' consolidated profit after tax fell to Rs 141.24 lakh in the quarter ended September 30, 2026, from Rs 8.04 crore in the corresponding 2025 quarter. Profit before tax declined to Rs 3.3332 crore from Rs 9.3991 crore, while revenue from operations increased to Rs 50.215 crore from Rs 43.9245 crore.

The principal difference between sales growth and total income was other income. Other income was Rs 2.159 crore in the September 2026 quarter, compared with Rs 6.6604 crore a year earlier. Consequently, total income fell to Rs 52.374 crore from Rs 55.5849 crore even as operating revenue increased by Rs 6.2905 crore.

The quarterly result also declined from the immediately preceding quarter. Profit after tax was Rs 1.9674 crore in the quarter ended June 30, 2026, compared with Rs 141.24 lakh in the September quarter, while revenue from operations rose from Rs 44.8789 crore to Rs 50.215 crore. Profit before tax decreased from Rs 3.8629 crore to Rs 3.3332 crore over the same comparison.

Which costs changed in Kilitch Drugs' September quarter?

Kilitch Drugs reported total expenses of Rs 49.0408 crore for the September 2026 quarter, compared with Rs 46.1858 crore a year earlier. Employee benefit expense increased to Rs 5.0523 crore from Rs 3.7583 crore, depreciation and amortisation rose to Rs 3.8219 crore from Rs 86.28 lakh, and other expenses increased to Rs 9.8308 crore from Rs 8.4916 crore.

Finance cost rose to Rs 1.6859 crore from Rs 1.4396 crore in the year-earlier quarter. Export product registration and commission was Rs 5.5026 crore, compared with Rs 5.2717 crore, while cost of materials consumed declined to Rs 23.7481 crore from Rs 24.2928 crore.

Changes in inventories of finished goods, work-in-progress and stock-in-trade were a credit of Rs 60.08 lakh in the September 2026 quarter. This compared with an expense of Rs 2.069 crore in the September 2025 quarter. The reported inventory movement partly offset increases in employee, finance, depreciation and other costs.

The expense pattern also changed sequentially. Total expenses were Rs 43.9129 crore in the June 2026 quarter, making the September-quarter figure higher by Rs 5.1279 crore. Depreciation and amortisation increased from Rs 1.0933 crore in June, and finance cost increased from Rs 87.64 lakh.

What do Kilitch Drugs' six-month results and cash flows show?

Kilitch Drugs recorded revenue from operations of Rs 95.0939 crore for the six months ended September 30, 2026, compared with Rs 92.0642 crore in the prior-year period. Profit after tax, however, declined to Rs 3.3798 crore from Rs 10.3024 crore, while profit before tax fell to Rs 7.1961 crore from Rs 12.8477 crore.

Total expenses for the six-month period increased to Rs 92.9537 crore from Rs 88.4343 crore. Employee benefit expenses rose to Rs 9.1886 crore from Rs 6.5103 crore, depreciation and amortisation reached Rs 4.9152 crore from Rs 1.706 crore, and other expenses increased to Rs 18.7224 crore from Rs 15.3771 crore.

Net cash flow from operating activities was Rs 1.3775 crore for the six months ended September 2026, compared with an outflow of Rs 6.6202 crore in the corresponding period. Capital expenditure on property, plant and equipment, capital work-in-progress and capital advances was Rs 18.0799 crore, contributing to an investing cash outflow of Rs 16.8734 crore.

Financing activities generated Rs 5.4127 crore during the six months, compared with Rs 81.3595 crore in the prior-year period. Cash and cash equivalents decreased by Rs 10.0832 crore during the period to Rs 5.6908 crore at September 30, 2026, from Rs 15.774 crore at March 31, 2026.

How did subsidiaries affect Kilitch Drugs' consolidated results?

Kilitch Drugs' foreign subsidiary reported revenue of Rs 6.7224 crore and a loss after tax of Rs 2.469 crore for the quarter ended September 30, 2026. For the six months from April 1 through September 30, 2026, it recorded revenue of Rs 10.6893 crore, a loss after tax of Rs 5.3344 crore and net cash outflow of Rs 4.7706 crore.

The foreign subsidiary had total assets of Rs 59.7347 crore at September 30, 2026. The consolidated auditor stated that its financial statements were furnished by management and that the auditor's conclusion on amounts relating to that subsidiary was based solely on those management-certified unaudited statements; the conclusion was not modified.

Monarchy Healthserve Private Limited, another subsidiary included in the consolidated results, had total assets of Rs 17.3062 crore. It reported nil revenue and a loss after tax of Rs 22.17 lakh for the September 2026 quarter, and a loss after tax of Rs 44.01 lakh for the six-month period.

Kilitch Drugs' consolidated balance sheet reported non-controlling interest of negative Rs 4.5055 crore at September 30, 2026, compared with negative Rs 2.7862 crore at March 31, 2026. Total consolidated assets were Rs 464.3034 crore at September 30, compared with Rs 457.7492 crore at the March 31 financial year-end.

What is Kilitch Drugs planning for Kilitch Estro Biotech PLC?

Kilitch Drugs has approved conversion of its entire outstanding debt, including service costs, of up to Rs 157 crore extended to Kilitch Estro Biotech PLC into equity shares of the Ethiopian material subsidiary. The company said the conversion is subject to compliance with the Foreign Exchange Management Act and other applicable laws.

Kilitch Drugs has also approved divestment of its entire shareholding in Kilitch Estro Biotech PLC, including additional shares arising from the proposed debt conversion, to HarmeeCare Pharmaceuticals. The disclosed aggregate consideration is USD 14 million for the 100% shareholding and settlement of Kilitch Estro Biotech PLC's existing debts and liabilities, of which USD 12.855 million would be payable to Kilitch Drugs.

The proposed divestment remains subject to applicable regulatory approvals and statutory compliance. The results filing does not state a completion date, a valuation in rupees, or the financial accounting effect of the conversion and proposed sale.

Conclusion

Kilitch Drugs' September-quarter results show that the 14% increase in revenue from operations did not result in higher reported earnings. Lower other income reduced total income year on year, while employee benefit expense, depreciation and amortisation, finance cost and other expenses were higher; the foreign subsidiary also reported a quarterly loss after tax of Rs 2.469 crore.

The next disclosed matter to watch is the proposed conversion of up to Rs 157 crore of Kilitch Estro Biotech PLC debt into equity and the planned disposal of the subsidiary to HarmeeCare Pharmaceuticals. Both transactions remain subject to regulatory approvals and statutory compliance, while the debt conversion also requires compliance with applicable foreign-exchange laws.